Prostate cancer incidence

There are 10 papers on prostate cancer incidence in aging research: 9 observational studies in people.

Disease

10 papers study it36 more mention it11 findings

5 new papers in 30 daysSee all 46 papers on prostate cancer incidence

“Furthermore, we observed an inverse association between BA measures and prostate cancer”
Clinical biomarker-based biological aging and risk of cancer in the UK BiobankBritish journal of cancer2023doi:10.1038/s41416-023-02288-w
  • Humans9
  • In silico1

Interventions

1

Spermidine

no changein humans1RR 1

1 study
  1. Spermidine was not clearly linked with prostate cancer incidence in humans (highest vs lowest quintile of dietary intake) (RR 1.00 (95% CI 0.89-1.12), highest vs lowest quintile).

    “The intake of spermidine was not associated with the incidence of prostate cancer”

    Humanshighest vs lowest quintile of dietary intakemales

    Dietary spermidine intake is not associated with prostate cancer incidence or prostate cancer-specific mortality: findings from the prostate, lung, colorectal, and ovarian cancer screening trial

    Frontiers in nutrition

More on Spermidine

Upstream

2

Northern regions of Brazil

upin humans1+2.6% annually

1 study
  1. Northern regions of Brazil is linked with higher prostate cancer incidence in Northern regions of Brazil (1990-2021) (+2.59% annually).

    “Northern regions showed lower rates but the steepest AAPC increases (e.g., incidence: + 2.59% annually in age group 70-74)”

    Humansin Northern regions of Brazil (1990-2021)males

    Global burden of prostate cancer (1990-2021) from Brazil: trends in disability-adjusted life years, incidence, mortality, and prevalence

    Cancer causes & control : CCC

Age

downin humans1

1 study
  1. age is linked with lower prostate cancer incidence in humans (Black vs White men) (-0.116 units per 5-year age group, 95% CI = -0.183 to -0.049).

    “relative PCa incidence for Black vs White men significantly decreases by 0.116 units with each successive 5-year age group (95% CI = -0.183 to -0.049)”

    HumansBlack vs White menmales

    Age-specific racial disparities in the incidence of fatal prostate cancer: an analytic deconstruction

    JNCI cancer spectrum

Associations

8

Angiotensin receptor blockers

upin humans1HR 1.14

1 study
  1. Angiotensin receptor blockers are associated with prostate cancer incidence in humans (Compared with RAS inhibitor non-use among antihypertensive medication users) (HR 1.14, 95% CI 1.02–1.27 versus RAS inhibitor non-use).

    “ARB use showed a modest association with higher prostate cancer incidence”

    HumansCompared with RAS inhibitor non-use among antihypertensive medication usersMean follow-up of 11.5 years

    Renin–Angiotensin System Inhibitor Use and Cancer Incidence Among <scp>UK</scp> Biobank Participants: A Prospective Cohort Study

    Cancer medicine

More on Angiotensin receptor blockers

Prostate cancer screening

upin humans1

1 study
  1. Prostate cancer screening is associated with prostate cancer incidence in humans (Population-based screening program; comparison with the pre-screening period) (34.7 cases/100,000 inhabitants (1988–1990) to 78 cases/100,000 (2008)).

    “PCa incidence increased significantly, from 34.7 cases/100,000 inhabitants (1988–1990) to 78 cases/100,000 (2008) (p=0.001).”

    HumansPopulation-based screening program; comparison with the pre-screening periodprostatemales

    A 20 years Follow-up Results of the Modena Screening Program for Prostate Cancer (PCa) "Progetto Uomo"(PU)

    Frontiers in oncology

More on Prostate cancer screening

Mailed psa information and testing program

upin humans1

1 study
  1. Mailed psa information and testing program is associated with prostate cancer incidence in humans (Regional trends after program implementation) (386 to 659 cases/100,000 per year).

    “Yearly prostate cancer incidence in the age group 50-74 years increased from 386 (2010-2013) to 659 cases/100 000 (2016-2019).”

    HumansRegional trends after program implementation2010–2013 versus 2016–2019males

    The 5-year outcomes of a regional population-based PSA information and testing programme

    BJU international

More on Mailed psa information and testing program

PSA density

upin humans1HR 1.41

1 study
  1. PSA density is associated with prostate cancer incidence in humans (without prostate cancer at baseline) (HR 1.41, 95% CI 1.30-1.52).

    “PSA density (HR, 1.41; 95% CI, 1.30-1.52) remained consistently associated with prostate cancer risk”

    Humanswithout prostate cancer at baseline20 yearsmalesn = 2,651

    Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years

    JAMA network open

More on PSA density

Prostate-specific antigen

upin humans1HR 1.06

1 study
  1. Prostate-specific antigen is associated with prostate cancer incidence in humans (without prostate cancer at baseline) (HR 1.06, 95% CI 1.04-1.07).

    “PSA (HR, 1.06; 95% CI, 1.04-1.07), and PSA density (HR, 1.41; 95% CI, 1.30-1.52) remained consistently associated with prostate cancer risk”

    Humanswithout prostate cancer at baseline20 yearsmalesn = 2,651

    Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years

    JAMA network open

More on Prostate-specific antigen

KDM biological age, PhenoAge and homeostatic dysregulation

downin humans1

1 study
  1. KDM biological age, PhenoAge and homeostatic dysregulation is associated with prostate cancer incidence in humans.

    “Furthermore, we observed an inverse association between BA measures and prostate cancer”

    HumansAssociation attenuated after removing glycated hemoglobin and serum glucose from the biological age algorithmsMedian follow-up of 10.9 years

    Clinical biomarker-based biological aging and risk of cancer in the UK Biobank

    British journal of cancer

More on KDM biological age, PhenoAge and homeostatic dysregulation

Psa testing

upin humans1

1 study
  1. Psa testing is associated with prostate cancer incidence in humans after 2000.

    “After 2000, changes in biopsies and incidence paralleled changes in PSA screening in men 45-84 years”

    Humansafter 2000males

    Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis

    Cancer epidemiology

More on Psa testing

Prostate-specific antigen screening

upin humans1

1 study
  1. Prostate-specific antigen screening is associated with prostate cancer incidence in humans (Population trends in Canada) (Incidence increased 12.8% per year after screening introduction, peaking at 140.8/100 000 in 1993).

    “Incidence was increasing before PSA screening occurred, but rose further after it was introduced.”

    HumansPopulation trends in Canadamales

    Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening

    CMAJ open

More on Prostate-specific antigen screening

Funding

1 grant since 2022

Prostate Cancer Foundation

Latest

Dec 2025: 1Jan 2026: 6Feb 2026: 3Mar 2026: 3Apr 2026: 1May 2026: 1Jun 2026: 0Jul 2026: 1Aug 2026: 1Sep 2026: 4Oct 2026: 3Nov 2026: 226 papers in 12 months

See all 46 papers on prostate cancer incidence